TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-JNJ-70099731
Description: \[18F\]JNJ-70099731 injection will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-JNJ-70099731
Description: \[18F\]JNJ-70099731 injection will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-JNJ-70099731
Description: \[18F\]JNJ-70099731 injection will be administered intravenously.
Study: NCT04218019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields
Description: The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
Study: NCT06202807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study: NCT06539780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting
Description: In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 60 minutes.
Study: NCT05426473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QuickDASH form
Description: Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
Study: NCT00414011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Description: 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
Study: NCT06073717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (\>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor-cognitive Training
Description: Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness
Description: Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.
Study: NCT05469854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan glurate
Description: Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, oral tablets
Study: NCT05606159

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus velezensis DSM 33864
Description: 1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.
Study: NCT05144477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAID Fear Intervention
Description: Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
Study: NCT06336174

Intervention type: DRUG
Intervention: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Description: All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.

Intervention type: PROCEDURE
Intervention: Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Description: All patients underwent endovascular therapy and received standard medical management after surgery, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
Study: NCT04218019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTFields
Description: The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
Study: NCT06568913

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBC
Description: Platelets counts in pediatric patient with perisistent or chronicITP unresponsive to steroids
Study: NCT05473247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ring-Fit Adventure Group
Description: Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.
Study: NCT06568107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental And Sensory Experience (EASE) intervention
Description: The participant will be exposed to 30 minutes of a still nature image and associated nature sounds (60-80 beats per minute). An brief interview will occur with the legally authorized representative to find out what nature scene would meet the preference of the person living with dementia and persistent vocalizations.
Study: NCT03850262

Intervention type: RADIATION
Intervention: MRI
Description: The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~* The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~* Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique.
Study: NCT05775237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin Gummies
Description: Chew gummies thoroughly and completely before swallowing.
Study: NCT04614519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low impact laparoscopy group
Description: Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
Study: NCT04107545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: athletes
Description: Control of body temperature using the bodyCap temperature monitor that records body temperature for up to 48h (three times)
Study: NCT05775237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C Gummies
Description: Chew gummies thoroughly and completely before swallowing.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin Gummies
Description: Chew gummies thoroughly and completely before swallowing.
Study: NCT05685693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted total knee arthroplasty (raTKA)
Description: Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional total knee arthroplasty
Description: total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
Study: NCT05459961

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral spermidine
Description: oral supplement
Study: NCT06469905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erector Spina Plan Block
Description: ESPB will be applied to the patients in the study group. Stabilization exercises will be applied together with ESPB treatment. The needle will be inserted between the erector spinae muscle and the transverse process structures.The local anesthetic will be monitored to spread along the erector spinae muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Description: Stabilization exercises will be practiced to control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Description: Stabilization exercises will be practiced to control group
Study: NCT05786677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy protocol
Description: the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~1. Suboccipital release~2. Diaphragm release~3. Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy protocol
Description: the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~1. Suboccipital release~2. Diaphragm release~3. Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI)
Description: Selective serotonin reuptake inhibitors (SSRIs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRI)
Description: Selective serotonin reuptake inhibitors (SSRIs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI)
Description: Selective serotonin reuptake inhibitors (SSRIs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRI)
Description: Selective serotonin reuptake inhibitors (SSRIs)
Study: NCT06058546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiuweihuaban Pill placebo
Description: Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose Jiuweihuaban Pill
Description: Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose Jiuweihuaban Pill
Description: High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
Study: NCT06581341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation and Percutaneous Tibial Nerve Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.~Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Tibial Nerve Stimulation
Description: Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used.
Study: NCT05482698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-25 cream
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MC2-25 vehicle
Description: Topical application
Study: NCT05154175

Intervention type: DEVICE
Intervention: Ottobock helmet
Description: Patients treated in current practice
Study: NCT06476171

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of the level of the studied biomarkers
Description: Determination of the level of hematological indices based on a general blood test; Determination of the levels of the following biomarkers: isolation of neutrophils from the blood using the gradient centrifugation method; assessment using enzyme immunoassay (ELISA) of the content of neutrophil elastase in the supernatant; myeloperoxidase, ELISA; lactoferrin, ELISA; interleukin -1ß,17,10,6, ELISA; presepsin, ELISA; endothelin, ELISA; lipopolysaccharide, LAL test; lipopolysaccharide binding protein, ELISA; NETs release, immunofluorescence method; the number of neutrophils expressing PDL-1, flow cytofluorimetry method; procalcitonin in human plasma and serum, VIDAS B.R.A.H.M.S. PCT; ferritin, reagent for determination (FERRITIN); lactate dehydrogenase, reagent for determination of QSR6128;Endotoxin Activity Assay, chemiluminescent immunodiagnostics.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of the level of the studied biomarkers
Description: Determination of the level of hematological indices based on a general blood test; Determination of the levels of the following biomarkers: isolation of neutrophils from the blood using the gradient centrifugation method; assessment using enzyme immunoassay (ELISA) of the content of neutrophil elastase in the supernatant; myeloperoxidase, ELISA; lactoferrin, ELISA; interleukin -1ß,17,10,6, ELISA; presepsin, ELISA; endothelin, ELISA; lipopolysaccharide, LAL test; lipopolysaccharide binding protein, ELISA; NETs release, immunofluorescence method; the number of neutrophils expressing PDL-1, flow cytofluorimetry method; procalcitonin in human plasma and serum, VIDAS B.R.A.H.M.S. PCT; ferritin, reagent for determination (FERRITIN); lactate dehydrogenase, reagent for determination of QSR6128;Endotoxin Activity Assay, chemiluminescent immunodiagnostics.
Study: NCT05357742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized basic need navigation and lifestyle coaching and skills training
Description: During each session participants will receive the manualized study intervention which includes 1) DKD education, 2) Individualized basic needs navigation, and 3) Lifestyle coaching and skills training. Participants will be provided a FORA 2-in-1 device with glucose test strips to allow testing at least once a day. The device automatically uploads blood pressure and glucose readings to a secure server in real time and the health educator will have access to this secure server. Readings will be used to guide lifestyle coaching and skills training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: During each session participants will receive DKD education only.
Study: NCT06465706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAmbre investigational device
Description: Randomized 1:1 to either experimental group or control group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAmbre investigational device
Description: Randomized 1:1 to either experimental group or control group.
Study: NCT04959279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED-TREAT
Description: Patients will be assessed and treated based on a clinical decision support system.
Study: NCT06536582

Intervention type: BIOLOGICAL
Intervention: Platelet rich growth factor injection (autologous product)
Description: All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.

Intervention type: BIOLOGICAL
Intervention: Platelet rich growth factor injection (autologous product)
Description: All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.